included 37 patients, 33 with chronic migraine and 4 with episodic. 81% were women, with an average age of 51±9 years, 13 received erenumab, 20 fremanezumab and 4 galcanezumab. Erenumab reduced the number of headache days by an average of 18 days in 7 patients, and the number of attacks halved in 8 and the consumption of symptomatic medication in 7. Only 14 patients with fremanezumab reached 12 weeks of therapy, 13 decreased the number of migraine days/month by an average of 11 days, 3 reduced the number of attacks by half, and 5 the consumption of symptomatic medication. Only 2 of 4 patients treated with galcanezumab decreased the number of days of migraine an average of 16 days, halved the number of attacks and the consumption of symptomatic medication. Treatment was discontinued for ineffectiveness in 12 patients (7 with erenumab, 3 with fremanezumab and 2 with galcanezumab). The most frequent adverse effects common to the three mAb were constipation and administration-related reactions. Erenumab also produced paresthesia (23%) and asthenia (8%). Conclusion and relevanceTaking into account that the number of patients was similar in both groups, fremanezumab has a better clinical benefit in reducing the number of days of migraine, and erenumab in reducing the number of attacks by half, and decrease the consumption of symptomatic medication, being generally well-tolerated drugs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.